1. Home
  2. PMM vs TTRX Comparison

PMM vs TTRX Comparison

Compare PMM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$5.77

Market Cap

269.4M

Sector

Finance

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$16.25

Market Cap

298.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMM
TTRX
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.4M
298.8M
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
PMM
TTRX
Price
$5.77
$16.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
82.0K
91.4K
Earning Date
01-01-0001
05-31-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.76
$2.57
52 Week High
$6.60
$14.50

Technical Indicators

Market Signals
Indicator
PMM
TTRX
Relative Strength Index (RSI) 21.50 75.45
Support Level N/A $3.49
Resistance Level $6.35 N/A
Average True Range (ATR) 0.07 1.31
MACD -0.03 0.32
Stochastic Oscillator 3.92 88.29

Price Performance

Historical Comparison
PMM
TTRX

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: